News

FDA Approves Actemra to Treat Adults With SSc-ILD

The U.S. Food and Drug Administration (FDA) has approved Actemra (tocilizumab) to slow lung function decline in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD). “We are honored to offer the very first FDA-approved biologic treatment option to…